The figure on the right shows surface modifications commonly pre-engineered in NanoParticles, in order to extend circulation half-life, reduce immunogenicity (typically, PEG chains), and thus improve targeting. The ligands, which allow these peculiar advantages,, are linked to NanoParticles surface together with the targeting system, such as antibodies, aptamers or small molecules, which bind surface proteins expressed on target cells or are capable to pilot the particles once inside the cell. Chemotherapy drugs, or other biologically active molecules encapsulated inside the NanoParticles, are released in the target site through a material-sensitive stimulus (Petros R.A. et al., “Strategies in the design of NanoParticles for therapeutic applications”, Nat. Rev. Drug Discov. 2010).
The use of nanotechnology in medicine, and in particular in drug delivery, is set to spread rapidly, more specifically for treating cancer, in order to reduce the side effects and toxicity of commonly used drugs.
AcZon NanoParticles, synthesized using dedicated biomolecules, are very interesting for drug administration applications, because they offer distinctive characteristics and great advantages (they spread widely and reach easily the target cells, providing a higher and more effective conentration of the drug in vivo).
Our experience in synthesis, doping, functionalization and conjugation of NPs enables us to incorporate drugs or other cytotoxic molecules inside nanomaterials, that can be bound to different biological systems, depending on specific requests of the Customer.